Test Pricing and Reimbursement in Genomic Medicine

Towards a General Strategy

Athanassios Vozikis, David N. Cooper, Christina Mitropoulou, Manousos E. Kambouris, Angela Brand, Vita Dolzan, Paolo Fortina, Federico Innocenti, Ming Ta Michael Lee, Lada Leyens, Milan Macek, Fahd Al-Mulla, Barbara Prainsack, Alessio Squassina, Domenica Taruscio, Ron H. Van Schaik, Effy Vayena, Marc S. Williams, George P. Patrinos

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

This paper aims to provide an overview of the rationale and basic principles guiding the governance of genomic testing services, to clarify their objectives, and allocate and define responsibilities among stakeholders in a health-care system, with a special focus on the EU countries. Particular attention is paid to issues pertaining to pricing and reimbursement policies, the availability of essential genomic tests which differs between various countries owing to differences in disease prevalence and public health relevance, the prescribing and use of genomic testing services according to existing or new guidelines, budgetary and fiscal control, the balance between price and access to innovative testing, monitoring and evaluation for cost-effectiveness and safety, and the development of research capacity. We conclude that addressing the specific items put forward in this article will help to create a robust policy in relation to pricing and reimbursement in genomic medicine. This will contribute to an effective and sustainable health-care system and will prove beneficial to the economy at large.

Original languageEnglish
Pages (from-to)352-363
Number of pages12
JournalPublic Health Genomics
Volume19
Issue number6
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Medicine
Delivery of Health Care
Costs and Cost Analysis
Budgets
Cost-Benefit Analysis
Public Health
Guidelines
Safety
Research

Keywords

  • Genomic medicine
  • Genomics education
  • Health economics
  • Pharmacogenomics
  • Policy
  • Public health genomics
  • Reimbursement
  • Whole genome sequencing

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Genetics(clinical)

Cite this

Vozikis, A., Cooper, D. N., Mitropoulou, C., Kambouris, M. E., Brand, A., Dolzan, V., ... Patrinos, G. P. (2017). Test Pricing and Reimbursement in Genomic Medicine: Towards a General Strategy. Public Health Genomics, 19(6), 352-363. https://doi.org/10.1159/000449152

Test Pricing and Reimbursement in Genomic Medicine : Towards a General Strategy. / Vozikis, Athanassios; Cooper, David N.; Mitropoulou, Christina; Kambouris, Manousos E.; Brand, Angela; Dolzan, Vita; Fortina, Paolo; Innocenti, Federico; Lee, Ming Ta Michael; Leyens, Lada; Macek, Milan; Al-Mulla, Fahd; Prainsack, Barbara; Squassina, Alessio; Taruscio, Domenica; Van Schaik, Ron H.; Vayena, Effy; Williams, Marc S.; Patrinos, George P.

In: Public Health Genomics, Vol. 19, No. 6, 01.01.2017, p. 352-363.

Research output: Contribution to journalArticle

Vozikis, A, Cooper, DN, Mitropoulou, C, Kambouris, ME, Brand, A, Dolzan, V, Fortina, P, Innocenti, F, Lee, MTM, Leyens, L, Macek, M, Al-Mulla, F, Prainsack, B, Squassina, A, Taruscio, D, Van Schaik, RH, Vayena, E, Williams, MS & Patrinos, GP 2017, 'Test Pricing and Reimbursement in Genomic Medicine: Towards a General Strategy', Public Health Genomics, vol. 19, no. 6, pp. 352-363. https://doi.org/10.1159/000449152
Vozikis A, Cooper DN, Mitropoulou C, Kambouris ME, Brand A, Dolzan V et al. Test Pricing and Reimbursement in Genomic Medicine: Towards a General Strategy. Public Health Genomics. 2017 Jan 1;19(6):352-363. https://doi.org/10.1159/000449152
Vozikis, Athanassios ; Cooper, David N. ; Mitropoulou, Christina ; Kambouris, Manousos E. ; Brand, Angela ; Dolzan, Vita ; Fortina, Paolo ; Innocenti, Federico ; Lee, Ming Ta Michael ; Leyens, Lada ; Macek, Milan ; Al-Mulla, Fahd ; Prainsack, Barbara ; Squassina, Alessio ; Taruscio, Domenica ; Van Schaik, Ron H. ; Vayena, Effy ; Williams, Marc S. ; Patrinos, George P. / Test Pricing and Reimbursement in Genomic Medicine : Towards a General Strategy. In: Public Health Genomics. 2017 ; Vol. 19, No. 6. pp. 352-363.
@article{d58a41159c714b1ba8a0ecadd665633b,
title = "Test Pricing and Reimbursement in Genomic Medicine: Towards a General Strategy",
abstract = "This paper aims to provide an overview of the rationale and basic principles guiding the governance of genomic testing services, to clarify their objectives, and allocate and define responsibilities among stakeholders in a health-care system, with a special focus on the EU countries. Particular attention is paid to issues pertaining to pricing and reimbursement policies, the availability of essential genomic tests which differs between various countries owing to differences in disease prevalence and public health relevance, the prescribing and use of genomic testing services according to existing or new guidelines, budgetary and fiscal control, the balance between price and access to innovative testing, monitoring and evaluation for cost-effectiveness and safety, and the development of research capacity. We conclude that addressing the specific items put forward in this article will help to create a robust policy in relation to pricing and reimbursement in genomic medicine. This will contribute to an effective and sustainable health-care system and will prove beneficial to the economy at large.",
keywords = "Genomic medicine, Genomics education, Health economics, Pharmacogenomics, Policy, Public health genomics, Reimbursement, Whole genome sequencing",
author = "Athanassios Vozikis and Cooper, {David N.} and Christina Mitropoulou and Kambouris, {Manousos E.} and Angela Brand and Vita Dolzan and Paolo Fortina and Federico Innocenti and Lee, {Ming Ta Michael} and Lada Leyens and Milan Macek and Fahd Al-Mulla and Barbara Prainsack and Alessio Squassina and Domenica Taruscio and {Van Schaik}, {Ron H.} and Effy Vayena and Williams, {Marc S.} and Patrinos, {George P.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1159/000449152",
language = "English",
volume = "19",
pages = "352--363",
journal = "Public Health Genomics",
issn = "1662-4246",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Test Pricing and Reimbursement in Genomic Medicine

T2 - Towards a General Strategy

AU - Vozikis, Athanassios

AU - Cooper, David N.

AU - Mitropoulou, Christina

AU - Kambouris, Manousos E.

AU - Brand, Angela

AU - Dolzan, Vita

AU - Fortina, Paolo

AU - Innocenti, Federico

AU - Lee, Ming Ta Michael

AU - Leyens, Lada

AU - Macek, Milan

AU - Al-Mulla, Fahd

AU - Prainsack, Barbara

AU - Squassina, Alessio

AU - Taruscio, Domenica

AU - Van Schaik, Ron H.

AU - Vayena, Effy

AU - Williams, Marc S.

AU - Patrinos, George P.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - This paper aims to provide an overview of the rationale and basic principles guiding the governance of genomic testing services, to clarify their objectives, and allocate and define responsibilities among stakeholders in a health-care system, with a special focus on the EU countries. Particular attention is paid to issues pertaining to pricing and reimbursement policies, the availability of essential genomic tests which differs between various countries owing to differences in disease prevalence and public health relevance, the prescribing and use of genomic testing services according to existing or new guidelines, budgetary and fiscal control, the balance between price and access to innovative testing, monitoring and evaluation for cost-effectiveness and safety, and the development of research capacity. We conclude that addressing the specific items put forward in this article will help to create a robust policy in relation to pricing and reimbursement in genomic medicine. This will contribute to an effective and sustainable health-care system and will prove beneficial to the economy at large.

AB - This paper aims to provide an overview of the rationale and basic principles guiding the governance of genomic testing services, to clarify their objectives, and allocate and define responsibilities among stakeholders in a health-care system, with a special focus on the EU countries. Particular attention is paid to issues pertaining to pricing and reimbursement policies, the availability of essential genomic tests which differs between various countries owing to differences in disease prevalence and public health relevance, the prescribing and use of genomic testing services according to existing or new guidelines, budgetary and fiscal control, the balance between price and access to innovative testing, monitoring and evaluation for cost-effectiveness and safety, and the development of research capacity. We conclude that addressing the specific items put forward in this article will help to create a robust policy in relation to pricing and reimbursement in genomic medicine. This will contribute to an effective and sustainable health-care system and will prove beneficial to the economy at large.

KW - Genomic medicine

KW - Genomics education

KW - Health economics

KW - Pharmacogenomics

KW - Policy

KW - Public health genomics

KW - Reimbursement

KW - Whole genome sequencing

UR - http://www.scopus.com/inward/record.url?scp=84989257383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989257383&partnerID=8YFLogxK

U2 - 10.1159/000449152

DO - 10.1159/000449152

M3 - Article

VL - 19

SP - 352

EP - 363

JO - Public Health Genomics

JF - Public Health Genomics

SN - 1662-4246

IS - 6

ER -